Cosmetic composition for skin soothing

Abstract

The present invention relates to a cosmetic composition, and provides a cosmetic composition comprising an amino acid-amino acid eutectic mixture and roxeutin as active ingredients, thus providing the effects of inhibiting inflammation and alleviating / reducing skin irritation.

Description

Cosmetic composition for skin soothing

[0001] The present invention relates to a cosmetic composition for skin soothing, and more specifically, to a technology for providing a composition comprising an amino acid-amino acid eutectic mixture and troxerutine as active ingredients, thereby exhibiting anti-inflammatory and skin irritation relief / reduction effects and providing the composition as a hypoallergenic external skin preparation or a skin soothing external skin preparation.

[0002]

[0003] There is a growing need among cosmetics users to effectively soothe sensitive or irritated skin. Furthermore, many of these consumers recognize that they have sensitive skin. This has led to a growing market for cosmetics specifically formulated for sensitive skin or for soothing skin. However, research on effective ingredients that can soothe sensitive skin or on synergistic combinations of these ingredients remains lacking.

[0004] The previously developed eutectic mixture (Korean Patent No. 10-2411385) shows excellent skin regeneration, collagen synthesis promotion, and skin elasticity improvement effects, but it is insufficient in soothing sensitive or irritated skin.

[0005] Derived from the Japanese locust tree (Sophora japonica), troxerutine acts as an antioxidant when applied topically, effectively scavenging free radicals and preventing oxidative stress. It is also known to protect the skin from UVB rays. However, troxerutine has the drawback of insufficient skin penetration.

[0006] Against this backdrop, the inventors of the present invention have made extensive efforts to enhance the skin soothing effect of the amino acid-amino acid eutectic mixture and to increase the skin permeability of troxerutine. As a result, they have completed the present invention by confirming the synergistic effect between the amino acid-amino acid eutectic mixture and troxerutine by using them together.

[0007]

[0008] One object of the present invention is to provide a cosmetic composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as active ingredients.

[0009]

[0010] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention should not be considered limited by the specific descriptions described below.

[0011]

[0012] In order to achieve the above-mentioned purpose, a cosmetic composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as active ingredients is provided.

[0013] In order to achieve the above-mentioned purpose, a method for soothing or anti-inflammation of the skin is provided, comprising a step of applying to the skin a composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as active ingredients.

[0014] In order to achieve the above-mentioned purpose, a method for soothing or anti-inflammation of the skin is provided, comprising a step of administering to a subject a composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as active ingredients.

[0015] In order to achieve the above-mentioned purpose, the present invention provides a composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as an active ingredient for manufacturing a skin soothing or anti-inflammatory cosmetic, food, or over-the-counter drug.

[0016]

[0017] Hereinafter, the present invention will be described in more detail.

[0018]

[0019] The term "skin soothing" of the present invention means soothing sensitive skin by irritation, suppressing the expression of inflammatory factors in the skin, and providing a refreshing feeling to the skin.

[0020]

[0021] The term "anti-inflammatory" of the present invention means protecting the skin, suppressing and preventing inflammation, and calming and resisting inflammation.

[0022]

[0023] The term "eutectic mixture" of the present invention refers to a eutectic compound formed by combining polar compounds, and may include amino acids, and may be an amino acid-amino acid eutectic mixture manufactured according to Korean Patent No. 10-2626486.

[0024] The above amino acid-amino acid eutectic mixture may be in the form of an amino acid-amino acid or an amino acid-amino acid-one or more solvents depending on the types of amino acids that constitute it, which is determined by the characteristics between the paired amino acids.

[0025] Specifically, the polar compound must have a difference in polarity, and the amino acid may be a compound having polarity. The polar amino acid may include polar amino acids, acidic amino acids, and basic amino acids. The polar amino acids may include serine, threonine, cysteine, tyrosine, asparagine, and glutamine, the acidic amino acids may include aspartic acid and glutamic acid, and the basic amino acids may include arginine, histidine, and lysine, and preferably, the compound may be an arginine glutamate eutectic mixture or a serine arginine eutectic mixture.

[0026]

[0027] The term "arginine" of the present invention refers to a chemical formula C6H 14It is N4O2 and is a basic amino acid. As an α-amino acid, L-arginine exists as an amino acid that constitutes proteins and belongs to the protein protamine present in fish sperm. In addition, it is a component of the ornithine cycle as a metabolic pathway in the body and is broken down into urea and ornithine by the action of arginase. It is a semi-essential amino acid required for the growth of children and animals. Specifically, the above arginine may be a basic amino acid.

[0028]

[0029] The term "glutamic acid" of the present invention is abbreviated as Glu, E, chemical formula C5H9NO4, molecular weight 147.13, a type of acidic α-amino acid, and was first discovered in gluten. L-glutamic acid is widely distributed in general proteins, and is particularly contained in large quantities in cereal proteins. Specifically, the glutamic acid may be an acidic amino acid.

[0030]

[0031] The total content of amino acids in the eutectic mixture may be 1 to 100 parts by weight, 5 to 90 parts by weight, 10 to 80 parts by weight, 15 to 70 parts by weight, 20 to 65 parts by weight, 30 to 60 parts by weight, 35 to 55 parts by weight, 40 to 50 parts by weight, or 42 to 47 parts by weight, based on 100 parts by weight of the entire eutectic mixture, but is not limited thereto.

[0032]

[0033] The above amino acid-amino acid eutectic mixture may additionally comprise one or more solvents.

[0034] The solvent may be one or more solvents selected from water, ethanol, methanol, and acetone, but is not limited thereto, and may be a solvent capable of dissolving an amino acid.

[0035] In the present invention, the solvent may be included in an amount of 0 to 98 parts by weight relative to 100 parts by weight of the entire eutectic mixture.

[0036] If the solvent content in the above eutectic mixture is 0, a stable eutectic mixture may be formed in an anhydrous form. However, if the solvent content exceeds 98 parts by weight, the eutectic mixture may not form due to impaired hydrogen bond stability, reverting to a normal mixture form. In this case, the skin permeability of troxerutine may decrease, making it difficult to achieve the desired effect.

[0037] Preferably, the eutectic mixture of the present invention may contain 10 to 90 parts by weight, 20 to 80 parts by weight, 30 to 70 parts by weight, or 40 to 60 parts by weight of the solvent relative to 100 parts by weight of the entire eutectic mixture, but is not limited thereto.

[0038]

[0039] The ratio of substances required for the eutectic mixture can be determined based on the charge of the molecules of the components forming the eutectic mixture, the type and number of functional groups of the molecules, and the polarity of the molecules or functional groups. Furthermore, the ratio of substances required for the eutectic mixture can be determined based on the size and similarity of the molecules.

[0040] The eutectic mixture formation ratio can be from 10:1 to 10:100 for each amino acid molar concentration.

[0041] Preferably, the eutectic mixture formation ratio may be such that the molar concentration of each amino acid is 1:1 to 1:3.

[0042] The eutectic mixture according to the present invention can have an acidity adjusted to have a value of pH 3 to pH 10 to improve discomfort such as skin irritation when applied to the skin. The eutectic mixture according to the present invention can be manufactured in a region where the amine group of the amino acid is structurally charged, and thus the region can have a pH of 3 or higher. For example, the eutectic mixture can be adjusted to have a weakly acidic to neutral acidity, such as pH 4 to pH 9, pH 5 to pH 8, or pH 6 to pH 7.

[0043] The eutectic mixture of the present invention can increase the stability of the composition by including an amino acid-amino acid or amino acid-amino acid-one or more solvents, due to the melting point lowering properties and solubility increasing properties of the eutectic mixture.

[0044] Because the skin efficacy of amino acids generally increases as pH decreases, conventional cosmetics have maintained a low pH. However, the eutectic mixture of the present invention reduces skin irritation that can occur at slightly acidic to neutral pH while increasing the skin permeability of amino acids. Thus, even at slightly acidic to neutral pH, the efficacy of amino acids can be maintained at the same high level as conventional cosmetics that maintain a low pH due to the increased permeability.

[0045]

[0046] The cosmetic composition according to the present invention contains the eutectic mixture in an amount of 0.001 to 50 parts by weight, for example, 0.01 to 50 parts by weight, 0.05 to 40 parts by weight, 0.05 to 30 parts by weight, 0.1 to 30 parts by weight, 0.1 to 25 parts by weight, 0.5 to 25 parts by weight, 0.1 to 50 parts by weight, 1 to 35 parts by weight, 5 to 30 parts by weight, 0.5 to 40 parts by weight, 1 to 30 parts by weight, 5 to 28 parts by weight, 8 to 25 parts by weight, 1 to 50 parts by weight, 5 to 40 parts by weight, 10 to 35 parts by weight, 15 to 25 parts by weight, 18 to 25 parts by weight, 15 to 20 parts by weight, 10 to 20 parts by weight, 10 to 30 The content of the eutectic mixture may be adjusted to suit the formulation of the cosmetic composition, but is not limited thereto.

[0047]

[0048] The term "troxerutin" of the present invention is a semi-synthetic substance derived from rutinoside, a flavonoid derived from Japanese ash tree, and inhibits the secretion of inflammatory mediators and factors acting on leukocytes and vascular endothelial cells involved in inflammatory metabolic reactions.

[0049] Specifically, when applied topically, troxerutine has been reported to act as an antioxidant, removing reactive oxygen species and preventing oxidative stress. It is also known to protect the skin from UVB rays. However, troxerutine has the disadvantage of low skin penetration.

[0050] Accordingly, the present invention includes an amino acid-amino acid eutectic mixture and troxetine as active ingredients, and confirmed the skin soothing and anti-inflammatory synergy effect exhibited by using them together through specific examples.

[0051] The content of the above troxerutine may be included in an amount of 0.0001 to 2 parts by weight based on 100 parts by weight of the total composition.

[0052] When the content of the above troxerutine is included in an amount of 0.0001 to 2 parts by weight relative to 100 parts by weight of the total composition, the anti-inflammatory factor inhibition effect or NO inhibition effect can be significantly increased.

[0053] The ratio of the above troxerutine: eutectic mixture may be 1:0.1 to 1:100, preferably 1:0.2 to 1:50, and more preferably 1:1 to 1:20.

[0054]

[0055] The composition may increase the skin permeation rate of troxerutine by 1.5 to 10 times compared to troxerutine alone.

[0056] Specifically, when the composition is applied to the skin, the skin permeation rate may be increased by 1.5 to 10 times compared to when troxerutine is applied to the skin alone. Preferably, the increase may be increased by 2 to 10 times.

[0057] When the above troxerutine is used alone, the skin permeation rate of troxerutine may be less than 0.1%, and thus the anti-inflammatory effect of the cosmetic composition may be minimal. However, the cosmetic composition of the present invention was confirmed to exhibit a synergistic effect by increasing the skin permeation rate of troxerutine by 1.5 to 10 times compared to when it is used alone by using it together with the eutectic mixture, thereby enhancing the skin soothing and anti-inflammatory effects.

[0058]

[0059] The cosmetic composition according to the present invention may additionally contain an oily component.

[0060] The above-mentioned oil component may be one or more oils or waxes. Any oil or wax commonly used as a cosmetic ingredient in the art may be used. For example, the oil may be a silicone oil, an ester oil, a triglyceride oil, a hydrocarbon oil, or a vegetable oil. One or more of these ingredients may be combined as needed.

[0061] For example, the silicone-based oil may be a silicone-based fluid oil or a silicone-based crosspolymer dispersed in oil. For example, silicone-based fluid oils that can be used include cyclopentasiloxane, cyclohexasiloxane, cycloheptasiloxane, cyclomethicone, cyclophenylmethicone, cyclotetrasiloxane, cyclotrisiloxane, dimethicone, capryl dimethicone, caprylyl trimethicone, caprylyl methicone, cetearyl methicone, hexadecyl methicone, hexyl methicone, lauryl methicone, myristyl methicone, phenyl methicone, stearyl methicone, stearyl dimethicone, trifluoropropyl methicone, cetyl dimethicone, diphenylsiloxyphenyl trimethicone, dimethylpolysiloxane, methylphenylpolysiloxane, decamethylcyclopentasiloxane, methyl trimethicone, or phenyl trimethicone. The above silicone oil components can be used alone or in combination with two or more types of oil. Silicone crosspolymers that can be used include, but are not limited to, dimethicone crosspolymer, dimethicone / vinyl dimethicone crosspolymer, dimethicone PEG-10 / 15 crosspolymer, or PEG-12 dimethicone / PPG-20 crosspolymer.

[0062] Ester oils include ascorbyl palmitate, ascorbillinoleate, ascorbyl stearate, diisostearyl malate, benzyl benzoate, benzyl laurate, butylene glycol dicaprylate / dicaprate, butylene glycol diisononanoate, butylene glycol aurate, butylene glycol stearate, butyl isostearate, cetearyl isononanoate, cetyl nonanoate, cetyl caprylate, cetyl ethylhexanoate, cetyl isononanoate, ethylhexyl caprylate / caprate, ethylhexyl isononanoate, ethylhexyl isostearate, ethylhexyl laurate, hexyl laurate, octyldodecyl isostearate, isopropyl isostearate. Isostearyl isononanoate, isostearyl isostearate, isocetyl ethylhexanoate, neopentyl glycol dicaprate, neopentyl glycol diethylhexanoate, neopentyl glycol diisostearate, pentaerythrityl stearate, pentaerythrityl tetraethylhexanoate, dipentaerythrityl hexaacid ester, polyglyceryl-2 diisostearate, polyglyceryl-2 sesquiisostearate, polyglyceryl-2 isostearate, polyglyceryl-2 tetraisostearate, polyglyceryl-2 triisostearate, polyglyceryl-3 diisostearate, polyglyceryl-3 isostearate, polyglyceryl-4 diisostearate, Polyglyceryl-4 isostearate, polyglyceryl-6 diisostearate, polyglyceryl-6 sesquiisostearate, or triethylhexanoin can be used.

[0063] Triglyceride oils that can be used include C8-C12 acid triglycerides, C12-C18 acid triglycerides, caprylic / capric / triglycerides, caprylic / capric / lauric triglycerides, C10-C40 isoalkyl acid triglycerides, C10-C18 triglycerides, glyceryl triacetyl hydrostearate, soybean glycerides, tribehenin, tricaprin, triethylhexanoin, triheptanoin, triisostearin, tripalmitin, or tristearin.

[0064] Hydrocarbon oils that can be used include liquid paraffin (mineral oil), paraffin, petrolatum, microcrystalline wax, or squalene.

[0065] Vegetable oils that can be used include avocado oil, wheat germ oil, rosehip oil, shea butter, almond oil, olive oil, macadamia oil, argan oil, meadowfoam oil, sunflower oil, castor oil, camellia oil, corn oil, safflower oil, soybean oil, rapeseed oil, macadamia nut oil, jojoba oil, palm oil, palm kernel oil, or coconut oil.

[0066] Any wax, such as hydrocarbon wax, vegetable wax, or silicone wax, commonly used in cosmetics, may be used as the wax. Examples thereof include, but are not limited to, candelilla wax, carnauba wax, rice wax, beeswax, lanolin, ozokerite, ceresin wax, paraffin wax, microcrystalline wax, C30-C45 alkyldimethylsilylpolypropylsilsesquioxane, ethylene / propylene copolymer, or polyethylene wax.

[0067] The content of the above-mentioned oil component is not particularly limited, and may be included in the remaining content excluding the eutectic mixture described above in the composition.

[0068]

[0069] The above cosmetic composition may be used for skin soothing.

[0070]

[0071] The cosmetic composition of the present invention comprises all kinds of ingredients that can be used in conventional cosmetics, such as humectants such as glycerin, butylene glycol, propylene glycol, hexanediol, methylgluceth-20, diglycerin, and ethylhexylglycerin; sunscreens such as ethylhexyl methoxycinnamate, ethylhexyl salicylate, ethylhexyl triazone, octocrylene, and bis-ethylhexyloxyphenol methoxyphenyl triazine; pH adjusters such as triethanolamine; thickeners such as carbomer, xanthan gum, acrylates / C10-30 alkyl acrylate crosspolymer, and hyaluronic acid; preservatives such as phenoxyethanol, methylparaben, and propylparaben; antioxidants such as BHT, ethyl ascorbyl ether, and ascorbic acid; skin conditioning agents such as beta-glucan; Surfactants such as cetearyl glucoside and sorbitan stearate; may additionally include fragrances or colors, but there is no limitation on the ingredients.

[0072] Each of the above-described components included in the cosmetic composition according to the present invention may be included in the cosmetic composition of the present invention within a range that preferably does not exceed the maximum usage amount stipulated in the “Cosmetics Safety and Technical Standards” established by the Chinese government.

[0073] The cosmetic composition according to the present invention can be manufactured in any formulation commonly manufactured in the art. For example, the cosmetic composition can have the formulation of, but is not limited to, a toner such as a flexible toner or a nourishing toner, a spray-type toner, an emulsion such as a facial lotion or a body lotion, a cream such as a nourishing cream, a moisturizing cream, an eye cream, etc., a stick, an essence, a cosmetic ointment, a spray, a gel, a pack, a sunscreen, a makeup base, a foundation such as a liquid type or a spray type, a makeup remover such as a powder, a cleansing lotion, a cleansing oil, a cleanser such as a cleansing foam, a soap, a body wash, etc.

[0074] In one specific example, the formulation of the cosmetic composition may be a toner skin solubilizing formulation, an O / W emulsion formulation, an O / W cream formulation, or a W / S cream formulation.

[0075] In the present invention, the "solubilized formulation" refers to a formulation in which a small amount of oil component is transparently dissolved in water, and is a formulation that exhibits transparency because the diameter of the oil drop is smaller than the wavelength of visible light and thus does not interfere with the straightness of light without scattering or reflection. The cosmetic composition having the solubilized formulation may be, but is not limited to, a transparent skin, toner, hair tonic, or hair liquid.

[0076] The cosmetic composition of the present invention can be used according to a conventional method of use, and the number of times it is used can vary depending on the user's skin condition or preference.

[0077]

[0078] Another aspect of the present invention for achieving the aforementioned object is to provide an anti-inflammatory composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as active ingredients.

[0079]

[0080] In a specific embodiment, it was confirmed that the cosmetic composition of the present invention can solve the problem of low skin permeability of troxerutine by increasing skin permeability compared to when troxerutine is used alone, and can provide a cosmetic composition with high skin soothing and anti-inflammatory effects.

[0081]

[0082] The advantages and features of the present invention, and the methods for achieving them, will become clearer with reference to the experimental examples and manufacturing examples described in detail below. However, the present invention is not limited to the experimental examples and manufacturing examples disclosed below, but may be implemented in various different forms. These examples are provided solely to ensure the complete disclosure of the present invention and to fully inform those skilled in the art of the invention of the scope of the invention.

[0083]

[0084] The cosmetic composition for skin soothing and anti-inflammatory use of the present invention comprises a eutectic mixture and troxerutine, and exhibits effects of increasing troxerutine permeability, suppressing inflammation, and relieving skin irritation, thereby providing a low-irritation skin external preparation or skin soothing external preparation.

[0085]

[0086] Hereinafter, the present invention will be described in more detail through examples. These examples are intended to explain the present invention more specifically, and the scope of the present invention is not limited by these examples.

[0087]

[0088] Example 1: Confirmation of NO expression inhibition effect

[0089] In order to confirm the anti-inflammatory effect of the cosmetic composition of the present invention, the NO production inhibition effect of each prepared sample was evaluated using Raw 264.7 cells.

[0090] Specifically, Raw 264.7 cells were pretreated with each sample for 30 minutes as shown in Table 1 below, and then 500 ng / ml LPS (Lipopolysaccharide) was added and cultured for 18 hours. After culture, the supernatant was transferred to a 96-well plate, GRIESS reagent was added, and the reaction was performed at room temperature for 15 minutes. The absorbance at 540 nm was measured using an ELISA reader, and the NO production inhibition ability was calculated using the following formula, and the results are shown in Table 1.

[0091] * NO production inhibition ability (%) = {1-(NO production amount when sample is added ÷ NO production amount when no sample is added)} × 100

[0092] * Positive control: 100 μM L-NMMA (80.9% inhibition of NO production)

[0093] * Negative control: RAW 264.7 cells treated with LPS only

[0094] NO production inhibition ability (%) Arginine glutamate eutectic mixture 10 ppm Arginine glutamate eutectic mixture 100 ppm Troxerutin 1 ppm Troxerutin 1 ppm + arginine glutamate eutectic mixture 0.1 ppm Troxerutin 1 ppm + arginine glutamate eutectic mixture 10 ppm Troxerutin 1 ppm + arginine glutamate eutectic mixture 18.4 Troxerutin 1 ppm + arginine glutamate eutectic mixture 100 ppm Positive control (L-NMMA) 100 μM 80.9

[0095] As shown in Table 1 above, the troxerutine or arginine glutamate eutectic mixture alone did not exhibit an inhibitory effect on the production of the inflammatory factor NO, whereas the combination of the 'troxerutine + arginine glutamate eutectic mixture' of the present invention was found to have an inhibitory effect on NO production, confirming the anti-inflammatory effect of the cosmetic composition of the present invention.

[0096]

[0097] Example 2: Confirmation of the effect of suppressing cytokine IL-1β expression

[0098] To confirm the anti-inflammatory effect of the combination of troxerutine and arginine glutamate eutectic mixture, the inhibitory effect on the production of capsaicin-induced cytokines in human keratinocytes was evaluated.

[0099] Specifically, human keratinocyte cell lines were pretreated with each sample for 1 hour as shown in Table 2 below, then 50 μm of capsaicin was added and cultured for 24 hours. After culture, RNA was extracted, cDNA was synthesized, and the amount of IL-1β was measured by polymerase chain reaction (real-time PCR). The results of the inhibitory ability of the sensitive inflammatory cytokine (IL-1β) production are shown in Table 2 using the following formula.

[0100] * Cytokine production inhibition ability (%) = [1-(gene expression fold when sample is added ÷ gene expression fold when no sample is added)] × 100

[0101] *Negative control: Human keratinocyte cell line treated with capsaicin only

[0102] IL-1β inhibition rate (%) Arginine glutamate eutectic mixture 10 ppm -0.73 Troxerutine 1 ppm 25.38 Troxerutine 1 ppm + arginine glutamate eutectic mixture 10 ppm 55.6

[0103] As shown in Table 2 above, the arginine glutamate eutectic mixture alone actually increased the expression of IL-1β, an inflammatory factor, and compared to the IL-1β expression inhibition rate of troxerutine alone, the combination of the troxerutine + arginine glutamate eutectic mixture of the present invention was confirmed to have an inflammatory factor inhibition effect that was more than twice as excellent, and it was confirmed that a synergistic effect was expressed by using the arginine glutamate eutectic mixture together with troxerutine.

[0104]

[0105] Example 3: Skin permeability evaluation

[0106] The skin permeability of a combination of troxerutine and arginine glutamate eutectic mixtures was evaluated.

[0107] Specifically, the skin absorption amount was evaluated using a Franz Cell (Labfine FCDV-15). A Transdermal Diffusion Testing Membrane (Merck Start-M 25 mm), which can predict skin permeability, was placed between the donor chamber and the receptor chamber, and 3 ml of PBS solution was added to the receptor chamber.

[0108] The evaluation method involved applying 100 μl of each of [1% troxerutine] and [1% troxerutine + 10% arginine glutamate eutectic mixture] onto the membrane. The membrane was then rolled 10 times for 30 seconds with a polyethylene stick and placed in a constant temperature and humidity chamber at 37.5°C and 50% relative humidity for 24 hours to allow permeation. The troxerutine content in the receptor chamber was then measured.

[0109] The concentration of troxerutine was determined by fluorescence spectrum measurement (Ex: 360 nm, measurement range: 380 to 700 nm). The concentration was quantified by the fluorescence intensity measured at 470 nm, and the permeation amount of troxerutine was calculated using the result and the volume of the extraction solvent. The results are shown in Table 3 below.

[0110] Troxerutin Penetration RateTroxerutin 1%0.86 μg0.086 %Troxerutin 1% + Arginine Glutamate Eutectic Mixture 10%2.06 μg0.206 %

[0111] As shown in Table 3 above, it was confirmed that the permeability of troxerutine increased approximately 2.4 times in the combination of troxerutine + arginine glutamate eutectic mixture compared to troxerutine alone. Therefore, it was confirmed that the skin permeability problem, which was previously known to be a problem with troxerutine, was also solved by the present invention.

[0112]

[0113] In summary of Examples 1 to 3 of the present invention, it was confirmed that the cosmetic composition of the present invention exhibits the effects of suppressing inflammation and alleviating / reducing skin irritation when provided as a hypoallergenic external agent or a skin soothing external agent.

[0114]

[0115] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts, rather than the detailed description above.

Claims

1. A cosmetic composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as active ingredients.

2. In paragraph 1, A cosmetic composition comprising the amino acid-amino acid eutectic mixture in an amount of 0.001 to 50 parts by weight relative to 100 parts by weight of the total composition.

3. In paragraph 1, A cosmetic composition wherein the amino acid-amino acid eutectic mixture comprises an arginine glutamate eutectic mixture or a serine arginine eutectic mixture.

4. In paragraph 1, A cosmetic composition wherein the content of the above troxerutine is included in an amount of 0.0001 to 2 parts by weight based on 100 parts by weight of the total composition.

5. In paragraph 1, The composition is a cosmetic composition characterized in that it increases the skin penetration rate of troxerutine by 1.5 to 10 times compared to troxerutine treatment alone.

6. In clauses 1 to 5, The above cosmetic composition is a cosmetic composition for soothing the skin.

7. An anti-inflammatory composition comprising an amino acid-amino acid eutectic mixture and Troxerutin as active ingredients.